Review Article / Преглед литературе

Amira Peco-Antić†

Pediatric renal stone disease
Обољења са бубрежним камењем код деце

Bel Medic Hospital, Belgrade, Serbia

Received: July 11, 2017
Revised: July 31, 2017
Accepted: August 1, 2017
Online First: August 8, 2017
DOI: https://doi.org/10.2298/SARH170711159P

* Accepted papers are articles in press that have gone through due peer review process and have been accepted for publication by the Editorial Board of the Serbian Archives of Medicine. They have not yet been copy edited and/or formatted in the publication house style, and the text may be changed before the final publication. Although accepted papers do not yet have all the accompanying bibliographic details available, they can already be cited using the year of online publication and the DOI, as follows: the author’s last name and initial of the first name, article title, journal title, online first publication month and year, and the DOI; e.g.: Petrović P, Jovanović J. The title of the article. Srp Arh Celok Lek. Online First, February 2017. When the final article is assigned to volumes/issues of the journal, the Article in Press version will be removed and the final version will appear in the associated published volumes/issues of the journal. The date the article was made available online first will be carried over.

† Correspondence to:
Amira PECO-ANTIĆ
5 Dr Nike Miljanića Street, 11000 Belgrade, Serbia
E-mail: amirapecoantic@yahoo.com
Pediatric renal stone disease

Обољења са бубрежним камењем код деце

SUMMARY
Pediatric renal stone disease is manifested as nephro/urolithiasis (UL) and/or nephrocalcinosis (NC). Compared to adults, UL in childhood is less common, and it is believed to be around 5% in industrialized countries, while the incidence of NC is even lower except for critically ill premature infants in whom it may reach 64%. The formation of UL and NC is caused by increased concentration of relevant solutes, and their aggregations and adherence to the renal tubules cell is facilitated by factors such as urine pH, inability of natural crystallization inhibitors, stasis of urine as well as renal tubule damage. UL is associated with significant morbidity because of pains, susceptibility to urinary tract obstruction and infections, and the necessity of surgical procedures. NC is usually asymptomatic but is frequently progressive, and more often than UL, leads to chronic renal failure. Although other imaging modalities can be used in the diagnosis of renal stone disease, ultrasound has the least risk and is most cost-effective. The majority cases of UL and NC in children are of metabolic origin and thus they are prone to recurrence and progression to chronic kidney failure.

Keywords: nephrolithiasis; nephrocalcinosis; metabolic disorders; children/chronic renal failure

INTRODUCTION
Pediatric renal stone disease is manifested as nephro/urolithiasis (UL) and/or nephrocalcinosis (NC). UL is characterized by stones that may be found anywhere in the urinary tract including kidney and/or ureter or bladder while NC is defined as calcium salt deposition in the renal parenchyma including the tubular epithelium and interstitial renal tissue [1]. Both, UL and NC may be discovered in children of all ages. Although other imaging modalities can be used in the diagnosis of UL/NC, ultrasound has the least risk and is most cost-effective.

UL/NC is associated with significant morbidity because of pains, susceptibility to urinary tract infections, the necessity of surgical procedures, and/or progression to chronic kidney failure. The most cases of UL and NC in children are of metabolic origin and thus they are prone to recurrence and
may cause chronic renal damage. Therefore, they deserve, even after their initial presentation a detailed metabolic evaluation.

There are important differences of UL and NC in children compared to those in adults. In this review article the epidemiology, pathophysiology, clinical manifestations, diagnosis, and treatment of the pediatric renal stone disease have been discussed. We paid the most attention to hypercalciuric renal stone diseases, as these are more likely to present in childhood.

**Epidemiology**

Compared to adults, UL in childhood is less common, and it is believed to be approximately 10% of that in adults, which is around 5% in industrialized countries [2-6]. The infants constitute up to one third of all pediatric UL patients [3, 4]. Overall, reported incidence of pediatric UL varies from 5.6 to 36/100000 children and adolescents younger than 18 years [5, 6]. Differences in incidence rates reported in children with UL reflect differences in genetic, geographic and socioeconomic background but also depend on the design and the time of the study [7]. Endemic UL is found in Southeast Asia, the Middle East, India, and Pakistan, while it is uncommon in children of African descent. It is very likely that the high consanguinity rate contributes to the higher incidence of UL/NC among ethnic groups that live in the Middle East and Asia. Additionally, the endemic calculi observed in these parts of the world are composed predominantly of ammonium and uric acid, and seem to correlate with dietary habits, malnutrition, urinary tract infections and hot climate. Epidemiology of UL in European nineteenth century population was similar, to that of the twentieth century in Asia [8]. Changes that have occurred in the socio-economic sphere, as well as their consequences, primarily in dietary habits (rich in proteins and calories), have influenced the incidence, the site (decreased rate of bladder stones) and chemical composition of calculi (raising rate of Ca oxalate and Ca phosphate stones) [7]. Like in adults [9] an increased trend of UL incidence so-called “stone wave”, has also been observed in children [10-15]. VanDervoort et al. demonstrated that pediatric UL increased almost five times over the last decade in United States [10]. An increasing incidence of UL may be explained at least partially by increasing rate of routine ultrasound examination in children with nonspecific as well as with specific symptoms. As in adults, UL is more common in males than in females [16], although there is some opposite finding [12]. Pediatric UL morbidity is responsible for 1/685 pediatric hospitalizations in United States [11] and 2.5/1000 pediatric hospitalizations in Croatia [17].

Incidence of NC in children is even less known than that of UL due to its typically asymptomatic course. Thus, NC diagnosis is usually made accidentally by ultrasound examination for other reasons. Due to the increasing application of ultrasound in recent times, NC is more frequent than previously revealed. NC epidemiology in neonate is much better known than in older children, especially in premature babies. It is all the greater if the gestational age and birth body weight of the newborn is less and its condition is more critical [18]. Jacinto JS et al. [19] reported NC incidence of 64% in the premature infants at a mean age of 39.3 +/- 26.7 days of life. Infants with NC had shorter
gestations (28.2 +/- 1.8 vs 31 +/- 1.4 weeks) and lighter birth weights (924 +/- 195 vs 1,338 +/- 100 g) than those infants without renal calcifications [19]. In another study [20], 26.6% of 79 infants born at less than 32 weeks' gestation developed NC. Affected infants were significantly smaller (mean birth weight 940g) and significantly less mature (mean gestation 26.9 weeks). Multivariate analysis showed that the strongest clinical indicator of NC was duration of oxygen treatment. Infants who still required oxygen treatment at 28 days of life had a 62% chance of developing renal calcification [20]. Other predisposing factors for NC in newborns are the use of diuretics (furosemide), corticosteroids, parenteral nutrition, and hypocytraturia.

**Pathophysiology**

A primary event in the formation of UL and NC is the increased concentration of relevant solutes (calcium phosphate, calcium oxalate, sodium urate, cystine or other substances) in urine above their saturation threshold due to their increased rate of urinary excretion and/or a low urine volume. The formation of crystals of the relevant salts, their aggregations and adherence to the renal tubules cell are also influenced by other factors such as urine pH, inability of natural crystallization inhibitors (citrate, pyrophosphate, sulfate, and magnesium), stasis of urine as well as renal tubule damage (due to urinary tract infections or some drugs). Crystal binding to the surface of tubular cells is facilitated by a number of luminal membrane molecules, including acidic fragment of nucleolin-related protein, annexin-II, osteopontin, and hyaluronan which are exclusively expressed at the luminal surface of regenerating/ (re)differentiating renal tubular cells [21].

Calcium oxalate is predominant constituent of at least 75% renal calcifications in pediatric as well as in adults from industrialized countries [21]. However, initial role in their formations have calcium phosphate crystals which starts forming apatite plaque (Randall plaques) at the basement membrane of the thin loops of Henle, location predisposed to urothelial erosion due to the urine flux [22]. Aggregations of calcium oxalate crystals at apatite plaques provide further stone formation attached to the papillary tip of the kidney. It is considered calcium-phosphate stone is developed from crystal aggregates deposited at the tip of the Bellini ducts [21].

The kidney itself has a great role in renal stone diseases in association with calcitropic hormones such as vitamin D3 and parathyroid hormone. The intrinsic renal calcium-sensing receptor (CaSR) feedback system, the regulation of paracellular calcium transport involving claudins, and new paracrine regulators such as klotho, give kidney a crucial position not only in modulation of calciuria but also of calcium homeostasis [23]. Genetic disorders in any of these systems may cause calcium nephropathy.

**Etiology**

As compared with the adult population, a higher proportion of pediatric patients have a well-defined etiology of renal stones. The etiology may be classified as metabolic, infection-related, structural urinary anomalies causing obstruction or idiopathic. Metabolic abnormalities account for
25% to 96% of UL/NC, while urinary tract infection and anatomical obstructive abnormalities account for 25% and 30%, respectively [24, 25]. Metabolic alterations include hypercalciuria, hypocitraturia, hyperuricosuria, phosphaturia with hypophosphatemia, distal renal tubular acidosis, idiopathic infantile hypercalcemia, Bartter and Dent diseases, familial hypomagnesemia with hypercalciuria and nephrocalcinosis, cystinuria, hyperoxaluria, and renal hypouricemia [26-31]. Heritability has been one of the strongest risks for UL/NC; 35% – 65% of affected patients will have relatives with UL/NC, compared with 5–20% of those without renal stone who have relatives with UL/NC [6, 27]. At least 30 genes have been shown to cause monogenic UL/NC by autosomal-dominant, autosomal-recessive, or X-linked transmission [28]. Polygenic disorders have also a significant role in UL, such as idiopathic hypercalciuria, but they are less cleared.

The study of Halbritter et al. which included an international cohort of 272 patients with UL/NC has shown that the percentage of monogenic cases was 11.4% in adult and 20.8% in pediatric patients cohorts [32]. Recessive monogenic diseases typically manifest earlier in life than dominant monogenic diseases [33]. In more than 40% of the cases in the aforementioned study, the genetic diagnoses contributed a new aspect to the previously established clinical diagnosis, suggesting practical implications, such as avoiding vitamin D (CYP24A1), initiating audiometry (ATP6V1B1), excluding the risk of recurrence in renal transplants (CLCN5 or CLDN16) or pyridoxine sensitivity in the presence of AGXT allele (Gly170Arg [32]. Based on the study results, Braun DA et al, give recommendation for clinicians to be aware of genetic source of UL/NC in the following conditions: early onset, familial prevalence, familial consanguinity, multiple or recurrent stones, and NC [33].

Hypercalciuria is the commonest metabolic abnormalities causing UL in children. It may be associated with increased, decreased or normal serum calcium levels (Tables 1–3). Idiopathic

**Table 1. Hereditary diseases associated with hypercalcemia and hypercalciuria (Modified [27]).**

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Clinical feature</th>
<th>Mode of inheritance</th>
<th>Gene product</th>
<th>Chromosomal location of the gene</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>FIHP</td>
<td>Familial isolated parathyroid tumors</td>
<td>A-r/A-d</td>
<td>Menin</td>
<td>11q13</td>
<td>PTH increased</td>
</tr>
<tr>
<td>MEN1</td>
<td>Parathyroid hyperplasia and/or tumors associated with pituitary and pancreatic-duodenal neuro-endocrine tumors</td>
<td>A-d</td>
<td>Menin</td>
<td>11q13</td>
<td>PTH increased</td>
</tr>
<tr>
<td>MEN2a</td>
<td>Parathyroid tumors with medullary thyroid cancer and pheochromocytoma</td>
<td>A-d</td>
<td>Ret</td>
<td>10q11.2</td>
<td>PTH increased</td>
</tr>
<tr>
<td>HPT-JT</td>
<td>Parathyroid tumors with ossifying fibromas of the jaw</td>
<td>A-d</td>
<td>Parafibromin</td>
<td>1q31.2</td>
<td>PTH increased</td>
</tr>
<tr>
<td>IHH</td>
<td>Idiopathic hypercalcemia with hypercalciuria</td>
<td>A-r</td>
<td>CYP24A1</td>
<td></td>
<td>PTH decreased</td>
</tr>
<tr>
<td></td>
<td>Hypophosphatemic nephrolithiasis/osteoporosis</td>
<td>A-d/A-r</td>
<td>NPT2a/SLC34A1</td>
<td>solute carrier family 34 (sodium phosphate), member 1/3</td>
<td>1,25 (OH)2D3 increased</td>
</tr>
</tbody>
</table>

A-d—autosomal dominant, A-r—autosomal recessive; FIHP—familial isolated hyperparathyroidism; MEN—multiple endocrine neoplasia; HPT-JT—hyperparathyroidism—jaw tumor syndrome; IHH—Idiopathic hypercalcemia with hypercalciuria; CASR—calcium-sensing receptor; NPT2a—sodium-phosphate co-transporter type 2c/a.
hypercalciuria (IH) is defined by hypercalciuria, normocalcemia, and absence of the known diseases that cause increased urine calcium excretion. In children hypercalciuria is diagnosed if the urine calcium excretion is \( \geq 0.1 \text{ mmol (} \geq 4 \text{mg)/kg/per day} \) in at least two separate collections of urine during 24 hours. Adequate collection is estimated via measuring 24 h urine creatinine of 0.1–0.2 mmol/kg/24h. In situations where 24 h urine collections is not possible, random urine measurements, using the spot urine ratio of the calcium and creatinine and compare with its age related reference values [34]. Pathogenesis of IH is very complex and many potential players are in the game such as polymorphisms of the genes coding for proteins regulating tubular phosphate and calcium reabsorption (VDR, SLC34A1, SLC34A4, CLDN14, and CaSR) and those responsible for proteins preventing calcium salt precipitation (CaSR, MGP, OPN, PLA2, and UMOD) or gene coding for a water channel in the proximal tubule (AQP1) [35]. Furthermore, in families with an autosomal dominant mode of IH inheritance connection between IH and loci on chromosome 1q23.3–q24, which contains the human soluble adenylyl cyclase (SAC) gene, chromosome 12q12–q14, which contains the vitamin D receptor (VDR) gene and chromosome 9q33.2–q34.2 were established [27]. Environmental factors may also significantly affect renal stone formation. Nutrient intake may change urine composition, but may also influence gene expression by epigenetic mechanisms [35].

**Clinical Manifestation**

Unlike adults and adolescents, only 10–14% of children with UL have classic renal colic [17, 34, 36]. Exceptionally, UL in children may be manifested by signs and symptoms of post renal acute kidney injury due to urethral or ureteral obstruction of both or single functioning kidney [37]. Instead, microscopic or macroscopic hematuria, flank or abdominal pain as well as recurrent urinary tract infection (UTI) are predominant clinical presentations of UL in children [16]. Hematuria may precede

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Clinical feature</th>
<th>Mode of inheritance</th>
<th>Gene product</th>
<th>Hromosomal location of the gene</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADHH</td>
<td>Hypocalcemia, Hyperphosphatemia, Hypomagnesemia</td>
<td>A-d</td>
<td>CASR</td>
<td>3q21.1</td>
<td>PTH low–normal range</td>
</tr>
<tr>
<td>FHHNC</td>
<td>Familial hypomagnesemia with hypercalciuria and nephrocalcinosis</td>
<td>A-r</td>
<td>PCLN1/CLDN16</td>
<td>3q28</td>
<td>PTH raised</td>
</tr>
<tr>
<td>FHHNC</td>
<td>Familial hypomagnesemia with hypercalciuria and nephrocalcinosis with ocular abnormalities</td>
<td>A-r</td>
<td>CLDN19</td>
<td>1p34.2</td>
<td>PTH raised</td>
</tr>
<tr>
<td>FIH</td>
<td>Hypoparathyroidism, familial isolated</td>
<td>A-d</td>
<td>GCM2</td>
<td>6p24.2</td>
<td>PTH low</td>
</tr>
<tr>
<td>APECED</td>
<td>Autoimmune polyendocriinopathy candidiasis ectodermal dystrophy</td>
<td>A-r</td>
<td>AIRE</td>
<td></td>
<td>PTH low</td>
</tr>
<tr>
<td>FIH, recessive</td>
<td>Hypoparathyroidism, autosomal recessive</td>
<td>A-r</td>
<td>11p153</td>
<td>PTH</td>
<td>PTH low</td>
</tr>
<tr>
<td>FIH-x linked</td>
<td>Hypoparathyroidism, familial isolated –x linked</td>
<td>X-r</td>
<td>GCM2</td>
<td>Xq26-q27</td>
<td>PTH low</td>
</tr>
<tr>
<td>FIH, dominant</td>
<td>Hypoparathyroidism, autosomal dominant</td>
<td>A-d</td>
<td>PTH</td>
<td>11p153</td>
<td>PTH low</td>
</tr>
</tbody>
</table>

A-d—autosomal dominant, A-r—autosomal recessive, X-r X-linked recessive, ADHH—autosomal dominant hypocalcemia with hypercalciuria, FHHNC—Familial hypomagnesemia with hypercalciuria and nephrocalcinosis, FIH—familial isolated hypoparathyroidism, APECED—Autoimmune polyendocriinopathy candidiasis ectodermal dystrophy, CASR—calcium-sensing receptor; PCLN1—paracellin; CLDN16/19—claudin 16/19.
progressive, and more often than UL, leads to chronic renal failure [28, 31, 34, 38].

During searching for causes of haematuria, abdominal pains, or sterile leukocyturia. NC is often finding during abdominal ultrasound imaging for any other reason [7, 34, 38].

Incontinence, suprapubic or urethral pain may be signs and symptoms of lower urinary tract dysfunction, such as nocturnal enuresis and or diurnal incontinence, which may be discovered as an incidental finding during abdominal ultrasound imaging for any other reason [7, 34, 38].

Nephrocalcinosis is usually asymptomatic or occult symptomatic and is diagnosed incidentally during searching for causes of haematuria, abdominal pains, or sterile leukocyturia. NC is often progressive, and more often than UL, leads to chronic renal failure [28, 31, 34, 38].

Table 3. Hereditary diseases associated with normocalcemia and hypercalciuria. Modified [27].

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Clinical feature</th>
<th>Mode of inheritance</th>
<th>Gene product</th>
<th>Chromosomal location of the gene</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>IH</td>
<td>Idiopathic hypercalciuria</td>
<td>AD</td>
<td>SACR / VDR</td>
<td>1q23.3-q24, 12q12-q14, 9q33.2-q34.2</td>
<td>Hypercalciuria, normocalcemia</td>
</tr>
<tr>
<td>Type I</td>
<td>+Hypercalciuria with nephrocalcinosis</td>
<td>A-r</td>
<td>SLC12A1/NKCC2</td>
<td>15q15-q21.1</td>
<td>Neonatal</td>
</tr>
<tr>
<td>Type II</td>
<td>+ Hypercalciuria with nephrocalcinosis</td>
<td>A-r</td>
<td>KCNJ1/ROMK</td>
<td>11q24</td>
<td>Neonatal</td>
</tr>
<tr>
<td>Type IV</td>
<td>+ Hypercalciuria with nephrocalcinosis + senoneural deafness + CRF</td>
<td>A-r</td>
<td>BSND/CLCNKB</td>
<td>1p31, 1p36</td>
<td></td>
</tr>
<tr>
<td>Type V</td>
<td>+ Hypercalciuria with nephrocalcinosis</td>
<td>A-d</td>
<td>CASR</td>
<td>3q21.1</td>
<td></td>
</tr>
<tr>
<td>Type VI</td>
<td>+ Dent</td>
<td>X-r</td>
<td>CLCN5</td>
<td>Xp11.22</td>
<td></td>
</tr>
<tr>
<td>Dent’s disease</td>
<td>Hypercalciuria, Phosphaturia, Hypophosphatemia, low molecular weight proteinuria, CRF</td>
<td>X-r</td>
<td>CLCN5</td>
<td>Xp11.22</td>
<td></td>
</tr>
<tr>
<td>Lowe’s syndrome</td>
<td>Psychomotor retardation, Fancony syndrome, Hypercalciuria, Phosphaturia, Megalin deficiency, Congenital cataract</td>
<td>X-r</td>
<td>OCRL1</td>
<td>Xq25</td>
<td></td>
</tr>
<tr>
<td>HHRH</td>
<td>Hypophosphatemic rickets with hypercalciuria</td>
<td>A-r</td>
<td>NPT2c/SLC34A3</td>
<td>9q34</td>
<td></td>
</tr>
<tr>
<td>dRTA A-d</td>
<td>Hypercalciuria, Hypocitraturia, Hypokalemia, rickets</td>
<td>A-d</td>
<td>SLC4A1/kAE1</td>
<td>17q21.31</td>
<td></td>
</tr>
<tr>
<td>dRTA with sensorineural deafness</td>
<td>Hypercalciuria, Hypocitraturia, Hypokalemia, rickets, Hearing loss</td>
<td>A-r</td>
<td>ATP6B1/ATP6V1B1</td>
<td>2p13</td>
<td></td>
</tr>
<tr>
<td>dRTA with preserved hearing</td>
<td>Hypercalciuria, Hypocitraturia, Hypokalemia, rickets</td>
<td>A-r</td>
<td>ATP6N1B/ATP6V0A4</td>
<td>7q34</td>
<td></td>
</tr>
</tbody>
</table>

**A-d**–autosomal dominant, **A-r**–autosomal recessive, **X-r**–X-linked recessive, **HHRH**–hereditary hypophosphatemic rickets with hypercalciuria, **dRTA**–distal renal tubular acidosis , **SAC** human soluble adenylyl cyclase; **VDR**–vitamin D receptor; **CASR**–calcium-sensing receptor; **SLC12A1**–solute carrier family 12, member 1; **NKCC2**–sodium–potassium–chloride co-transporter 2; **KCNJ1**–potassium channel, inwardly rectifying, subfamily J, member 1; **ROMK**–renal outer medullary potassium channel; **CLCNKB**–chloride channel 5; **BSND** Barttin; **CLCN5**–chloride channel 5; **OCRL1**–oculo-cerebro-renal syndrome of Lowe 1; **NPT2c**–solute carrier family 34, member 1/3; **SLC34A1**–solute carrier family 34, member 1; **kAE1**–kidney anion exchanger 1; **ATP6B1**–ATPase, H+ transporting (vacuolar proton pump), V1 subunit B1; **ATP6N1B** ATPase, H+ transporting, lysosomal V0 subunit a4.

noticeable UL for some time. Recurrent UTI or unexplained sterile pyuria in young children should arouse suspicion of UL. Recurrence rate of UL may be as high as 50% at 5 years [27]. In addition, signs and symptoms of lower urinary tract dysfunction, such as nocturnal enuresis and or diurnal incontinence, suprapubic or urethral pain may be found in about 10% of children with UL [7]. Finally, 10-25% of young children have no symptoms of UL than which may be discovered as an incidental finding during abdominal ultrasound imaging for any other reason [7, 34, 38].
Table 4. Normal values of solute for 24 h urine collection, or for spot urine samples: creatinine ratios (solute/creatinine). Modified from reference [34].

<table>
<thead>
<tr>
<th>The age specific parameters values</th>
<th>Ratio of solute to creatinine</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mmol/mmol</td>
<td>mg/mg</td>
</tr>
<tr>
<td><strong>Calcium</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| <12 months                       | <2        | 0.81    | < 0.1 mmol (< 4 mg)/kg/24 h  
After meals with milk excretion increase up to 40%. |
| 1–3 years                        | <1.5      | 0.53    |         |
| 3–5 years                        | <1.1      | 0.39    |         |
| 5–7 years                        | <0.8      | 0.28    |         |
| >7 years                         | <0.6      | 0.21    |         |
| **Oxalati**                      |           |         |         |
| 0–6 months                       | <325–360  | 288–260 | <0.5 mmol (<45 mg)/1.73 m²  
For the primary hiperoksaluriju types I and II examine also urinary glycolate, L-glycerol and oxalate in plasma. |
| 7–24 months                      | <132–174  | 110–139 |         |
| 2-5 years                        | <98–101   | 80      | >1.9 mmol (365 mg)/1.73 m² (M); >1.6 mmol (310 mg)/1.73 m² (F)  
>180 mg (94 µmol/g (8.84 mmol) creatinine  
Decreased: RTA, premature infants, hypokalemia, renal transplantation |
| 5-14 years                       | <70-82    | 60-65   | >0.4 mmol (0.8 mg)/kg ; >88 mg (44 mmol)/1.73 m²/24 h  
There is no data for children <2 years. |
| >16 years                        | <40       | 32      |         |
| **Citrate**                      | g/g       |         |         |
| 0-5 years                        | >0.25     | 0.42    | >180 mg (94 µmol/g (8.84 mmol) creatinine  
Decreased: RTA, premature infants, hypokalemia, renal transplantation |
| >5 years                         | >0.15     | 0.25    | >0.4 mmol (0.8 mg)/kg ; >88 mg (44 mmol)/1.73 m²/24 h  
There is no data for children <2 years. |
| **Magnesium**                    | 0.63      | >0.13   | >0.04 mmol (0.8 mg)/kg ; >88 mg (44 mmol)/1.73 m²/24 h  
There is no data for children <2 years. |
| **Phosphates**                   | TmP/GFR   |         |         |
| <3 months                        | <3.3 mmol/l |         |         |
| <6 months                        | <2.6 mmol/l |         |         |
| 2-15 years                       | <2.44 mmol/l |         |         |
| **Sodium**                       | <3 mmol/kg/24 h |         |         |
| **Potassium**                    | >3 mmol/kg/24 h |         |         |
| **Acidum uricum**                | Age >2 years <0.56 mg/dl (33 µmol/l) / GFR (ratio × serum creatinine) | <815 mg (4.9 mmol)/1.73 m²/24 h or <35 mg (0.21 mmol)/kg/24 h  
Higher in childhood than in adults.  
There is no data for children <2 years. |
| **Xantine**                      | 30-90 µg (20–60 µmol) / 24 h |         |         |
| **Cystin**                       | <60 mg (0.5 mmol) / 1.73 m²/24 h | <10 years<55 µmol (13 mg)/1.73 m²;  
>10 years<200 (48 mg)/1.73 m² |         |

GFR–glomerular filtration rate; TmP/GFR–tubular maximum reabsorption rate of phosphate to glomerular filtration rate.
DIAGNOSTIC EXAMINATION

Given the complexity of children's UL/NC and especially its predominant metabolic hereditary etiology it is advised, as the best solution, to perform the systemic diagnostic evaluation and personalized treatment in the Center for Pediatric renal stone disease, as it is practice in some Western countries [36]. System diagnostic evaluation includes a detailed medical history, careful and complete physical examination which is then followed by imaging studies and specific blood and urine analyses. In medical history, special attention should be given to information on family renal stones, hematuria, renal failure, but also on diet habits, fluid intake, medications, vitamin and mineral supplements, immobilization, chronic bowel diseases, and of course, on urological anomalies and urinary tract infections [34].

Diagnostic imaging should be start with ultrasound examination which is of wide availability, non invasive, without ionized radiation, and very useful to detect kidney stones, obstructive anomalies, and other aspects of the urinary tract anatomy [34]. Usually, renal ultrasound is the only method that is required, but for detection of small stones or stones in the ureter, computed tomography (CT) is more sensitive than ultrasound. Conventional radiography, with, or without contrast (plain x-ray) may replace CT in infants and young children as not require sedation and give less ionizing radiation. However radiolucent uric acid stones cannot be visualized by conventional radiography while struvite (magnesium ammonium phosphate), cystine stones, and stones composed of some drugs (ceftriaxone) can be difficult to be detected from the surrounding tissue. For diagnosis of NC in children, high-resolution renal ultrasound is the optimal method due to its high sensitivity (96%), and very good specificity (85%) [39].

A complete analysis of the first morning urine is an essential in diagnosis of UL / NC. By microscopic urine examination it is possible to differentiate glomerular from non-glomerular hematuria, to diagnose crystals (e.g. hexagonal cystine crystals, orange-brown 2,8 dihydroxy-adenine), to notice leucocytes, and bacteria. Urine pH (done by glass electrode or, by pH paper), urine specific gravity or osmolality, urine protein and glucose are part of the routine examination of urine. It is important to note that the results of urinalysis are credible only in the absence of urinary tract infection. Therefore, urine culture is check prior to the start chemical urine analysis which includes measurement of creatinine, calcium, uric acid, oxalic acid, phosphate, magnesium and citrate. Cystine is examined by nitroprusside test or by amino acid chromatography. It is preferable to be done from 24 h, but when it is unavailable can be replaced by the spot urine ratio of the test substance and creatinine (Table 4). All patients should also be examined for serum calcium, phosphorus, magnesium, uric acid, alkaline phosphatase, pH, bicarbonate, and creatinine. In patients with hypercalciuria it is advised to do blood analyses for parathyroid hormone (PTH), vitamin D metabolites and vitamin A. For the diagnosis of primary hyperoxaluria it is required to measure plasma and urine oxalate, and glycolate and L-glycerate in urine. Determination of intestinal oxalate absorption and stool Oxalobacter formigenes colonization is preferable for secondary hyperoxaluria.
Finally, genetic tests are required to confirm clinical diagnosis and are very useful for personalized treatment and preventive strategy [27-33].

**Therapy**

In case of acute renal colic, pain is usually very intense due to irritation of receptors during dilatation of the urinary system and release of pain mediators through to local irritation and swelling of the wall of the renal pelvis or ureter. The use of nonsteroidal antiinflammatory drugs (NSAIDs) may be indicated as first choice. Renal stone expulsive treatment may be managed with open surgery, extracorporeal shock wave lithotripsy (ESWL), laparoscopic or robot-assisted uretero-pyelolithotomy, percutaneous nephrolithotomy (PCNL), rigid and/or flexible ureteroscopy (URS) and medical expulsive treatment (MET) [40]. Choice of the treatment for a specific patient is determined based on the renal stone location, its size, and composition, urinary system anatomy, as well as available technology, cost of the treatment, experience of the physician, and preference of both the physician, and the patient’s parents [40]. Alpha-blockers and calcium channel blockers have been found to be more effective and successful for MET than other drugs (antimuscarinic drugs, phosphodiesterase type-5 inhibitors and steroids) [40]. Both of them eliminate or alleviate uncoordinated contractions induced by the stone and do not affect the normal peristalsis of the ureter. MET may be useful for small stones (5-10 mm) within the distal part of ureter, and usually are applied after ESWL treatment.

Non-pharmacological measures are still the initial and basic treatment and preventive measures [38]. These include an increase in urine output and crystallization inhibitors, and the setting of optimal urine pH. Increased the intake of fluid (≈3l / m² of body surface area) provides urine output > 1 ml / kg / h [38]. Reduced intake of salt (NaCl) and increased potassium intake should maintain ratio of Na / K in urine <2.5 [38]. It should not reduce calcium intake below the age recommended ( 800 mg per day for pre-school and 1300 mg of school age) because of the increased risk for osteopenia and hyperoxaluria. It is advised also to reduce intake of animal protein. The intake of phytate and magnesium should increase while reducing intake of sucrose, fructose, and high doses of vitamin C [38].

Pharmacological measures are specific regarding the etiology of UL/NC. For hypercalciuria and/or hypocitraturia it is advised to give K citrate (0.5 - 1.5 mEq or 0.1-0.15 g / kg body weight per day divided into 2 or 3 doses each) which is metabolized to bicarbonate in the liver and thus reduces intratubular citrate reabsorption and therefore increases urinary citrate excretion. Citrate forms a complex with calcium, reducing precipitation of calcium with other substances such as oxalate. Thiazides (hydrochlorothiazide 1-2 mg / kg / day divided into 1-2 doses) with or without amiloride [38] decrease also calcium urine excretion. In patients with dominant hypocalcemia, hyperphosphatemia and hypercalciuria due to a gain-of-function CaSR mutation, vitamin D is not indicated as it worsens hypercalcemia and hypercalciuria. For hypercalciuria + phosphaturia, phosphates are given. Treatment options for CYP24A1 mutation disorders include avoidance of
vitamin D supplementation, sunlight exposure and tanning beds along with high water intake [41], but in severely affected patients, treatment with the cytochrome inhibitor ketoconazole may be beneficial [42].

For primary hyperoxaluria type I, besides a large water intake (>3 l/m2/day), citrate or orthophosphate, vitamin B6 (5-20 mg / kg / day) is given which may in about 30% of patients (those with a distinct allele - Gly170Arg) enhance the reduced activity of alanine/glyoxylate aminotransferase (AGT), thus reducing hyperoxaluria. In others, hepatic AGT activity should be restored by liver transplantation. Sequential liver-kidney or liver combine with kidney transplantation is performed in patients with advanced stages of chronic kidney failure. In secondary (absorptive) hyperoxaluria it is necessary to treat primary gastrointestinal disease, to reduce the intake of oxalate in the food, increase the intake of calcium (to bind fatty acid thereby preventing the intestinal absorption of oxalate), with potassium citrate, and probiotics.

Hyperuricosuria is treated by alkalinization of urine (by potassium citrate), dietary purine restriction and, if needed, allopurinol can be added.

In patients with cystinuria, urine pH should be kept between 7.0 and 7.5 by potassium citrate and bicarbonate, besides abundant rehydration. Specific drugs for cystinuria are tiopronin, D-penicillamine and captopril which cleave cystine into two cysteine-disulfide moieties that are 50-times more soluble than cystine. However, care must be taken of their side effects.

In distal renal acidosis, treatment of acidosis by potassium citrate and bicarbonate is the cornerstone of therapy.

CONCLUSION

UL/NC in children is very important problem due to its complications and possibility to cause chronic renal failure. Every child with renal stone should undergo the diagnostic evaluation. For all UL/NC etiologies early identification and personalized treatment of the basic disorder is the most important.

REFERENCES


DOI: https://doi.org/10.2298/SARH170711159P Copyright © Serbian Medical Society